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We identified several chromosomal regions yielding
suggestive LOD scores, including the HLA region on
chromosome 6. These intervals could harbor potential
susceptibility loci for alopecia areata. In order to exclude
those regions that represent spurious positive scores and
to confirm and refine the true susceptibility loci, we are
currently undertaking a fine-mapping study in a larger group
of AA families.
We anticipate that these studies will lead to the
identification of AA susceptibility genes, and provide a
foundation for understanding the interactions of these
gene(s) with each other and with other variables such as
the immune system and environmental factors.
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Neurotrophins are a family of structurally and functionally
related polypeptides that include nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), neurotrophin-3,
and neurotrophin-4 (for a review see Roux and Barker,
2002). They bind a 75kDa transmembrane neurotrophin
receptor (p75NTR), and also each neurotrophin binds a
distinct receptor of the Trk family. When p75NTR and Trk are
coordinately bound by neurotrophins, survival signal is
initiated through Trk. But in absence of the Trk, p75NTR is
activated alone to induce a variety of cellular responses
including apoptosis.
Increased evidence of data suggests that neurotrophins
play an important role during the development of auto-
immune disorders: NGF levels are significantly increased in
the synovium of patients affected by rheumatoid arthritis, in
the cerebrospinal fluid of patients with multiple sclerosis, in
plasma of patients affected by lupus erythematosus, and in
the skin of patients with systemic scleroderma (for a review
see Aloe and Tuveri, 1997). The mechanisms of neurotro-
phin involvement in pathogenesis of autoimmune disorders,
however, are largely unknown. Because neurotrophins are
expressed in skin affected by alopecia areata (AA) and
promote hair follicle regression in normal non-affected skin
(Botchkarev et al, 2000; Botchkarev, 2003), we asked if
neurotrophins may play a role in AA pathogenesis.
CD8 lymphocytes were isolated from involved skin and
peripheral blood of AA-affected C3H/HeJ mice as well as
from non-affected control mice. In contrast with peripheral
blood CD8 cells that displayed low p75 levels, cells from AA
involved skin expressed significantly higher p75 level
(po0.001, FACScan analysis). Multi-color immunofluores-
cence microscopy showed that p75-positive CD8 cells were
assembled specifically around the hair follicles as well as
inside the follicular epithelium.
To identify the phenotype of CD8 cells expressing
p75NTR in skin affected by AA, the expression of
interferon-g (IFN-g) and granzyme B as markers of effector
CD8 cells was studied by FACS analysis and immunofluor-
escence. p75NTR-positive CD8 cells also showed the
expression of IFN-g and granzyme B suggesting their
effector phenotype. By RT-PCR, however, these cells were
negative for Trk (TrkA, TrkB, TrkC) receptor expression,
suggesting that neurotrophin administration could induce
apoptosis of these inflammatory cells.
Consistent with this hypothesis, NGF- and BDNF-
induced apoptosis in CD8 cells isolated from skin of mice
affected by AA and cultured in vitro, as compared with
diluent alone. Furthermore, in vivo administration of agarose
beads soaked with NGF or BDNF resulted in significant
reduction of CD8 cells (po0.01) in AA-affected skin. These
data suggest that neurotrophin-stimulated apoptosis in CD8
cells may play a role as a part of the protective response
mechanisms limiting the development of AA and that
p75NTR agonists could be used as a novel therapeutic
intervention to arrest the development of AA.
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Alopecia areata (AA) was regarded as a type 1 (Th1, Tc1)-
mediated autoimmune disease of the hair follicle, because
type 1 cytokines interferon-g (IFN-g) and interleukin (IL)-2
are expressed in lesional AA skin. Recently we have shown
that the type 2 (Th2, Tc2) cytokine IL-10 also is expressed in
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skin-infiltrating leukocytes in AA of C3H/HeJ mice and that
IL-10/ mice are resistant to the development of AA,
pointing toward an involvement of type 2 cytokines in AA
pathogenesis. To prove the functional relevance of type 1
cytokines in AA, we induced AA in IFN-g/ mice and in IL-
2þ / mice by grafting lesional AA skin from AA-affected
mice.
Conclusions
Our data show that IFN-g/ mice are resistant to the
development of AA, pointing toward an important role of
IFN-g in the pathogenesis of AA. The absence of a
perifollicular lymphocytic infiltrate in the skin and the
reduced expression of T cell activation markers and co-
stimulatory molecules in skin-draining lymph nodes demon-
strate that T cells are not activated in the lymph nodes of
IFN-g/ mice. Therefore, we conclude that IFN-g is
involved in T cell activation in AA pathogenesis of C3H/
HeJ mice.
A pathogenetic role for IL-2 in AA could also be
demonstrated, but the cogency of our data is limited
because only heterozygous IL-2þ / mice were available
for these experiments. But Holla¨nder et al (Science 1998)
demonstrated that IL-2 expression is reduced 50% in IL-
2þ / mice compared with IL-2þ /þ mice. Our data show
that the frequency of AA development is significantly
reduced in IL-2þ / mice. Therefore, we conclude that
the magnitude of IL-2 expression influences the frequency
of AA development. FACS analysis and immunohistochem-
istry show that AA resistance of half of the IL-2þ / mice is
related to a reduced Tcell activation in the lymph nodes and
an absence of perifollicular infiltrates of CD4þ and CD8þ
cells in the skin. These data suggest that AA development in
the C3H/HeJ mouse model depends on the level of IL-2
expression and on subsequent T cell activation in the lymph
nodes.
Taken together, our results show that the type-1
cytokines IFN-g and IL-2 are involved in T cell activation in
the development of AA in the C3H/HeJ mouse model.
Methods and Results
After experimental induction of AA by skin grafting, 90% of normal
C3H/HeJ mice (control) developed AA, whereas none of the IFN-
g/ mice and only 47% of IL-2þ / mice developed AA.
Immunohistochemistry of skin sections showed dense peri- and
intrafollicular infiltrates of CD4þ and CD8þ cells in control mice
with AA, whereas perifollicular infiltrates were absent in IFN-g/
and IL-2þ / mice without AA.
FACS analysis of skin-draining lymph node cells and skin-
infiltrating leukocytes of IFN-g/ mice revealed a significant
reduction of the T cell activation markers and of co-stimulatory
molecules. In IL-2þ / mice the expansion of CD4þ T cells was
reduced and the upregulation of activation markers and costimu-
latory molecules was impaired.
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We pioneered anticytokine therapy, proposing anti-IFN
(interferon) and anti-TNF-a (tumor necrosis factor) to treat
autoimmune diseases (AD) (Skurkovich et al, 2002).
Evidence is accumulating that alopecia areata (AA) may
be a Th-1 mediated AD of the hair follicle (Arca et al, 2004).
Based on this and our hypothesis that all Th1 AD may have
a similar basis—disturbed IFN-g synthesis—with varying
clinical manifestations depending on the site of the
disturbance (Skurkovich et al, 2002), we administered
anti-IFN-g intramuscularly (IM) to patients with AA. Anti-
IFN-g antibodies were produced by immunizing goats with
recombinant human IFN-g, isolating the IgG, and preparing
F(ab0)2 fragments. Sixteen AA patients (age 6–15 years)—
nine with patchy, progressive disease (positive hair pull test
at periphery of patches), five with 100% scalp hair loss,
some with eyebrows and/or eyelashes preserved, and two
patients with patchy, stable hair loss were treated. Duration
of illness ranged from 6 m to 5 y (mean 2.75 y), size of areas
of hair loss from 3 to 12 cm in diameter, and the number of
patches of hair loss from 1 to 4. Patients were given 1 mL IM
injections of anti-IFN-g twice daily for five successive days.
Most patients were observed monthly up to 6 mo after
completion of therapy. AA was accompanied by psoriasis
vulgaris and vitiligo in one patient each.
Of the 16 patients treated, eight of the nine patients with
patchy, progressive hair loss stabilized after 3 days of
therapy and showed no additional hair loss. After 4–6 mo
(with one patient observed only 3 mo), these patients
showed partial, but on-going (four), or full (four) terminal,
i.e., fully restored, hair-growth including eyebrows and/or
eyelashes, with one having no response. By 6 mo only one
of these patients had any recurrence (one 1.5 cm lesion
which appeared 5 mo post-treatment) with the rest
maintaining or continuing their improvement. Of the five
patients with 100% baldness, three had some limited
terminal hair growth; the other two showed only vellus hair
or no response. Of the two patients with stable, patchy hair
loss, one showed complete eyelash and eyebrow hair
restoration, but neither showed scalp hair growth.
The accompanying cases of vitiligo and psoriasis also
improved, confirming good results using anti-IFN-g to treat
these diseases. Since best results were obtained in patients
with patchy, progressive hair loss (positive hair pull test at
periphery of patches), the results support early intervention
as most effective. In the cases of total hair loss, repeated
courses of injection, possibly with humanized monoclonal
antibodies, may give a better outcome. The immediacy and
high rate of response to the injections argue against
spontaneous remission of the disease as an explanation
for the improvement.
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